Compile Data Set for Download or QSAR
Report error Found 301 of ki for UniProtKB: P06870
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM50034582(Peptide boronate | CHEMBL2448441)
Affinity DataKi:  0.00490nMAssay Description:Binding affinity against kallikreinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357210(US10214512, Example 151-a)
Affinity DataKi:  0.160nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357151(US10214512, Example 110-a | (Z)-5-(3-Chloro-2,6-di...)
Affinity DataKi:  0.210nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357155(US10214512, Example 114-a | (Z)-5-(3-chloro-2,6-di...)
Affinity DataKi:  0.240nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357153(US10214512, Example 112-a | (Z)-5-(3-Chloro-2,6-di...)
Affinity DataKi:  0.260nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357026(5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(24-((me...)
Affinity DataKi:  0.290nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357192(US10214512, Example 145-a)
Affinity DataKi:  0.300nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357094(US10214512, Example 71)
Affinity DataKi:  0.330nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357152(US10214512, Example 111-a | (Z)-5-(3-chloro-2,6-di...)
Affinity DataKi:  0.340nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357057(US10214512, Example 37)
Affinity DataKi:  0.360nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357188(US10214512, Example 143-b)
Affinity DataKi:  0.400nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357166(US10214512, Example 122 | US10214512, Example 125)
Affinity DataKi:  0.430nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357143(US10214512, Example 102-a | (Z)-5-(5-Chloro-2-(dif...)
Affinity DataKi:  0.430nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357065((S)-2-(24-(((2-(tert-butoxy)ethoxy)carbonyl)amino)...)
Affinity DataKi:  0.440nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357110(9-(5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-1-oxido...)
Affinity DataKi:  0.460nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357139(US10214512, Example 98-a | (Z)-5-(5-chloro-2-(1H-t...)
Affinity DataKi:  0.490nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357206(US10214512, Example 150-a)
Affinity DataKi:  0.510nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357099(5-(3-chloro-2,6-difluorophenyl)-2-((5R,9S)-15-fluo...)
Affinity DataKi:  0.530nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357022(5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-((5R,9S)...)
Affinity DataKi:  0.590nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357137(US10214512, Example 96-a | (Z)-5-(3-chloro-2,6-dif...)
Affinity DataKi:  0.600nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357161(US10214512, Example 117)
Affinity DataKi:  0.650nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357174(US10214512, Example 130)
Affinity DataKi:  0.660nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357055(US10214512, Example 35)
Affinity DataKi:  0.700nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357196(US10214512, Example 146-a)
Affinity DataKi:  0.710nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357168(US10214512, Example 124)
Affinity DataKi:  0.730nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357172(US10214512, Example 128)
Affinity DataKi:  0.740nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357150(US10214512, Example 109-a | (Z)-5-(3-chloro-2,6-di...)
Affinity DataKi:  0.770nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357157(US10214512, Example 114-c)
Affinity DataKi:  0.780nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357164(US10214512, Example 120)
Affinity DataKi:  0.780nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357059(US10214512, Example 39)
Affinity DataKi:  0.810nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357056(5-(5-chloro-2-(4-(difluoromethyl)-1H-1,2,3-triazol...)
Affinity DataKi:  0.810nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357058(US10214512, Example 38)
Affinity DataKi:  0.950nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357149(US10214512, Example 108-a | (Z)-2-(24-Amino-4-OXO-...)
Affinity DataKi:  1.02nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357141(US10214512, Example 100-a | (Z)-5-(3-Chloro-6-(dif...)
Affinity DataKi:  1.02nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357096(US10214512, Example 73)
Affinity DataKi:  1.08nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357194(US10214512, Example 145-c)
Affinity DataKi:  1.10nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357140(US10214512, Example 99-a | (Z)-5-(5-chloro-2-(trif...)
Affinity DataKi:  1.21nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357118(US10214512, Example 86-a | 5-(3-Chloro-2,6-difluor...)
Affinity DataKi:  1.29nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357191(US10214512, Example 144)
Affinity DataKi:  1.35nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357226(US10214512, Example 161 | (Z)-5-(3-chloro-2-fluoro...)
Affinity DataKi:  1.35nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357231(US10214512, Example 166-a)
Affinity DataKi:  1.39nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357167(US10214512, Example 123)
Affinity DataKi:  1.41nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357075(5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-2-(15-fluo...)
Affinity DataKi:  1.43nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357208(US10214512, Example 150-c)
Affinity DataKi:  1.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357100(5-(3-chloro-2,6-difluorophenyl)-2-((5S,9S)-15-fluo...)
Affinity DataKi:  1.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357066((S)-5-(3-chloro-2,6-difluorophenyl)-2-(24-(((2-hyd...)
Affinity DataKi:  1.53nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357033(5-(3-Chloro-2,6-difluorophenyl)-2-(24-((methoxycar...)
Affinity DataKi:  1.55nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357048(methyl (9-(5-(3-chloro-2- fluoro-6-(1h-tetrazol-1-...)
Affinity DataKi:  1.57nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357187(US10214512, Example 143-a)
Affinity DataKi:  1.61nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357053(US10214512, Example 33)
Affinity DataKi:  1.67nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

Displayed 1 to 50 (of 301 total ) | Next | Last >>
Jump to: